Yu Mei
Yu Mei — Chief Physician — Gynecologic Oncology — Peking Union Medical College Hospital
Specialties
Individualized comprehensive decision-making and diagnosis and treatment of various benign and malignant gynecological tumors, including: 1. Endometrial cancer, endometrial hyperplasia, ovarian cancer, ovarian tumors, ovarian cysts, cervical cancer, cervical lesions, vulvar cancer, etc.; ● To standardize the diagnosis and treatment of gynecological tumors, served as the primary author in writing the "Recommendations for Endometrial Cancer Screening Standards," and participated extensively in the formulation and publication of multiple expert consensus documents, including "Chinese Expert Consensus on Fertility-Sparing Multidisciplinary Treatment of Endometrial Cancer," "Chinese Expert Consensus on Surgical Staging of Cervical Cancer (2023 Edition)," and "Expert Guidance on Breast Cancer Screening for Patients with Germline BRCA Mutations in Ovarian Cancer (Including Fallopian Tube Cancer and Primary Peritoneal Cancer) (2022 Edition)," among others; ● Actively promoted the clinical application of targeted therapy for ovarian cancer and molecular testing of gynecological tumors nationwide, serving as a main executor at the Xiehe sub-center participating in China's first nationwide multicenter study on niraparib maintenance treatment for recurrent ovarian cancer; interim data confirmed clinical benefit, and for the first time, whole-exome sequencing technology was used to study the gene mutation landscape of Chinese ovarian supportive stromal tumor patients, laying a preliminary foundation for tumor gene testing and genetic counseling; ● Particularly skilled in fertility-preserving treatment for various gynecological malignancies, genetic counseling for gynecological malignancies, and treatment of adolescent gynecological tumors. 2. Chemotherapy, targeted therapy, and immunotherapy for gynecological malignancies, as well as genetic counseling for gynecological malignancies based on molecular testing, and fertility-preserving treatment for gynecological malignancies.
Education
Studied under Academician Lang Jinghe of the Chinese Academy of Engineering, Doctor of Clinical Medicine of the 8-year program at Peking Union Medical College
Professional Experience
Female, Chief Physician, Professor, Master's Supervisor, Core Expert at the Gynecologic Oncology Center of Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Visiting Scholar at Memorial Sloan Kettering Cancer Center (MSKCC) in New York, USA. ● Has been deeply engaged in the frontline clinical care, research, and teaching of gynecologic oncology for nearly 20 years, focusing on standardized, precise, and individualized diagnosis and treatment of benign and malignant gynecologic tumors. Core treated diseases include the three major malignant tumors: endometrial cancer, cervical cancer, and ovarian cancer, as well as benign tumors such as cervical intraepithelial neoplasia, ovarian cysts, and uterine fibroids. She is also proficient in the diagnosis and treatment of rare and complex gynecologic tumors such as vulvar and vaginal cancers. She sees over 5,000 outpatients annually, performs 400-500 high-difficulty level III/IV surgeries as the chief surgeon, successfully tackles numerous critical and complicated cases, and has an excellent clinical reputation, widely recognized by patients and peers. ● Notable technical advantages include expertise in fertility-preserving treatment for gynecologic malignancies to maintain reproductive potential for young patients; proficiency in genetic counseling for hereditary gynecologic tumors (Lynch syndrome, BRCA mutations), providing high-risk populations with accurate risk assessment, and supporting early prevention and intervention of tumors. She is skilled in molecular targeted therapy and immunotherapy, complex and challenging gynecologic tumor radical surgery/minimally invasive surgery, as well as multidisciplinary management of recurrent and metastatic gynecologic tumors, strictly adhering to the principle of balancing radical tumor treatment with patient quality of life. ● Strong academic and research capabilities, leading or being a core participant in more than 10 national-level projects including the 14th Five-Year and 11th Five-Year National Key R&D Programs and National Natural Science Foundation projects; led the largest domestic endometrial cancer screening study (covering 58 hospitals and over 50,000 cases), drafted the "Endometrial Cancer Screening Standard Recommendations," participated in formulating six national-level gynecologic oncology expert consensus guidelines, co-authored over 10 authoritative monographs, holds two invention patents, and has published over 40 academic papers in core domestic and international journals. As a key project member, she participated in multiple international multicenter phase III clinical studies of Niraparib, promoting the standardized application of PARP inhibitors in ovarian cancer treatment and contributing to reshaping the treatment landscape of advanced ovarian cancer.
Professional Roles
● Member and Secretary of the Gynecologic Oncology Branch of the Beijing Medical Association; ● Member of the Tumor Endocrinology Committee of the Chinese Anti-Cancer Association; ● Member of the Genetics and Eugenics Group of the Family Planning Society of the Chinese Medical Association; ● Deputy Chair of the Women’s Health Branch of the Research Society of the Chinese Society of Geriatric Health Care; ● Standing Committee Member of the Gynecologic Oncology Special Committee of the Beijing Chronic Disease Prevention and Health Education Association; ● Medical Dispute Liability Assessment Expert of the Medical Legal Work Committee of the Beijing Health Law Society; ● Editorial and Review Expert for the Nominal Terms Achievement Transformation and Standardization Promotion Project of the National Administration of Traditional Chinese Medicine;